Possible Role of Purinergic Signaling in COVID-19

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2021 Mar 19

PMID 33740184

Citations 22

Authors

Maria Luiza Mukai Franciosi

Millena Daher Medeiros Lima

Maria Rosa Chitolina Schetinger

Andreia Machado Cardoso

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease (COVID-19), caused by SARS-CoV-2 infection, accounts for more than 2.4 million deaths worldwide, making it the main public health problem in 2020. Purinergic signaling is involved in the pathophysiology of several viral infections which makes the purinergic system a potential target of investigation in COVID-19. During viral infections, the ATP release initiates a cascade that activates purinergic receptors. This receptor activation enhances the secretion of pro-inflammatory cytokines and performs the chemotaxis of macrophages and neutrophils, generating an association between the immune and the purinergic systems. This review was designed to cover the possible functions of purinergic signaling in COVID-19, focusing on the possible role of purinergic receptors such as P2X7 which contributes to cytokine storm and inflammasome NLRP3 activation and P2Y1 that activates the blood coagulation pathway. The possible role of ectonucleotidases, such as CD39 and CD73, which have the function of dephosphorylating ATP in an immunosuppressive component, adenosine, are also covered in detail. Moreover, therapeutic combination or association possibilities targeting purinergic system components are also suggested as a possible useful tool to be tested in future researches, aiming to unveil a novel option to treat COVID-19 patients.

Citing Articles

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

Receptors Involved in COVID-19-Related Anosmia: An Update on the Pathophysiology and the Mechanistic Aspects.

Al-Saigh N, Harb A, Abdalla S Int J Mol Sci. 2024; 25(15).

PMID: 39126095 PMC: 11313362. DOI: 10.3390/ijms25158527.

Genetic Polymorphisms of P2RX7 but Not of ADORA2A Are Associated with the Severity of SARS-CoV-2 Infection.

Lindo J, Nogueira C, Soares R, Cunha N, Almeida M, Rodrigues L Int J Mol Sci. 2024; 25(11).

PMID: 38892324 PMC: 11173306. DOI: 10.3390/ijms25116135.

A Prospective Study Investigating Immune Checkpoint Molecule and CD39 Expression on Peripheral Blood Cells for the Prognostication of COVID-19 Severity and Mortality.

Gambichler T, Ruth J, Goesmann S, Hoxtermann S, Skrygan M, Susok L Viruses. 2024; 16(5).

PMID: 38793691 PMC: 11125582. DOI: 10.3390/v16050810.

Purinergic signaling in the battlefield of viral infections.

Carvalho-Barbosa N, Zeidler J, Savio L, Coutinho-Silva R Purinergic Signal. 2023; .

PMID: 38038801 DOI: 10.1007/s11302-023-09981-8.

References

Pfaffenzeller M, Franciosi M, Cardoso A . Purinergic signaling and tumor microenvironment in cervical Cancer. Purinergic Signal. 2020; 16(1):123-135. PMC: 7166227. DOI: 10.1007/s11302-020-09693-3. View

Berlin D, Gulick R, Martinez F . Severe Covid-19. N Engl J Med. 2020; 383(25):2451-2460. DOI: 10.1056/NEJMcp2009575. View

Merad M, Martin J . Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20(6):355-362. PMC: 7201395. DOI: 10.1038/s41577-020-0331-4. View

Di Virgilio F, Adinolfi E . Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303. PMC: 5269532. DOI: 10.1038/onc.2016.206. View

Ledderose C, Bao Y, Kondo Y, Fakhari M, Slubowski C, Zhang J . Purinergic Signaling and the Immune Response in Sepsis: A Review. Clin Ther. 2016; 38(5):1054-65. PMC: 4875817. DOI: 10.1016/j.clinthera.2016.04.002. View

Antonioli L, Blandizzi C, Pacher P, Hasko G . The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. Pharmacol Rev. 2019; 71(3):345-382. PMC: 6592405. DOI: 10.1124/pr.117.014878. View

Della Latta V, Cabiati M, Rocchiccioli S, Del Ry S, Morales M . The role of the adenosinergic system in lung fibrosis. Pharmacol Res. 2013; 76:182-9. DOI: 10.1016/j.phrs.2013.08.004. View

Burnstock G, Boeynaems J . Purinergic signalling and immune cells. Purinergic Signal. 2014; 10(4):529-64. PMC: 4272370. DOI: 10.1007/s11302-014-9427-2. View

Cekic C, Linden J . Purinergic regulation of the immune system. Nat Rev Immunol. 2016; 16(3):177-92. DOI: 10.1038/nri.2016.4. View

10.

Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F . Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383(2):120-128. PMC: 7412750. DOI: 10.1056/NEJMoa2015432. View

11.

Polak S, Van Gool I, Cohen D, von der Thusen J, van Paassen J . A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020; 33(11):2128-2138. PMC: 7306927. DOI: 10.1038/s41379-020-0603-3. View

12.

Paces J, Strizova Z, Smrz D, cerny J . COVID-19 and the immune system. Physiol Res. 2020; 69(3):379-388. PMC: 8648321. DOI: 10.33549/physiolres.934492. View

13.

Tay M, Poh C, Renia L, Macary P, Ng L . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-374. PMC: 7187672. DOI: 10.1038/s41577-020-0311-8. View

14.

Liao F, Peng D, Chen W, Hu H, Tang P, Liu Y . Evaluation of serum hepatic enzyme activities in different COVID-19 phenotypes. J Med Virol. 2020; 93(4):2365-2373. DOI: 10.1002/jmv.26729. View

15.

Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P . Coronavirus infections and immune responses. J Med Virol. 2020; 92(4):424-432. PMC: 7166547. DOI: 10.1002/jmv.25685. View

16.

Di Virgilio F, Tang Y, Sarti A, Rossato M . A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Br J Pharmacol. 2020; 177(21):4990-4994. PMC: 7280564. DOI: 10.1111/bph.15138. View

17.

Abouelkhair M . Targeting adenosinergic pathway and adenosine A receptor signaling for the treatment of COVID-19: A hypothesis. Med Hypotheses. 2020; 144:110012. PMC: 7303042. DOI: 10.1016/j.mehy.2020.110012. View

18.

Antonioli L, Fornai M, Blandizzi C, Pacher P, Hasko G . Adenosine signaling and the immune system: When a lot could be too much. Immunol Lett. 2018; 205:9-15. DOI: 10.1016/j.imlet.2018.04.006. View

19.

Zhou Y, Mohsenin A, Morschl E, Young H, Molina J, Ma W . Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol. 2009; 182(12):8037-46. PMC: 3631106. DOI: 10.4049/jimmunol.0900515. View

20.

Olotu C, Lehmensiek F, Koch B, Kiefmann M, Riegel A, Hammerschmidt S . inhibits purinergic signaling and promotes purinergic receptor P2Y internalization in alveolar epithelial cells. J Biol Chem. 2019; 294(34):12795-12806. PMC: 6709641. DOI: 10.1074/jbc.RA118.007236. View